

Suffering from Chronic Fatigue Syndrome? It May be Due to EBV Infection; The CBCD Examines the Medical Evidence

A study found a link between latent EBV and CFS. (1)

ROCHESTER, NEW YORK, UNITED STATES OF AMERICA, April 17, 2016 /EINPresswire.com/ --

“Infected with the EBV virus? We recommend taking [Gene-Eden-VIR](#) or [Novirin](#).” – Greg Bennett, CBCD

More than one study suggests that infection with the latent Epstein-Barr Virus (EBV) may be responsible for Chronic Fatigue Syndrome (CFS). In fact, in one study, Dr. Loebel and colleagues found that patients with CFS have a lot of viral proteins expressed during the latent phase of the virus (1). In a latent condition, the virus is hidden, and does not produce any obvious symptoms. Most people with a latent infection will never suspect that they are infected. This is important since the CDC notes that “Chronic fatigue syndrome, or CFS, is a debilitating and complex disorder characterized by profound fatigue that is not improved by bed rest and that may be worsened by physical or mental activity.” (2)

EBV is a common virus and most individuals become infected by the time they become adults. Dr. Loebel explains how the virus may cause CFS even when it is not active. “CFS onset typically goes along with a viral illness... (and)...for many years, researchers have suspected EBV to be involved in CFS. A hallmark of CFS is chronic activation of the immune system, which can be triggered by infections...” Study

authors found no evidence for an active EBV infection in CFS patients. Instead, there was evidence



for a latent infection with the Epstein Barr Virus. “We had no evidence of lytic replication as we could neither detect EBER DNA in plasma nor BZLF-1 RNA in PBMCs. Thus, our findings suggest a higher level of latency-associated replication in CFS patients.” (1) Their study was published in PLoS One in January 2014.

Click to learn more about [EBV symptoms](#).

In another study, Hanan Polansky and Edan Itzkovitz, wrote that “Most scientists and physicians believe that latent viruses cause no pathologies or symptoms. The FDA even states on its website: ‘Some viruses, however, can enter a state known as latency in which the virus is not being replicated. In the latent state, the virus does not cause disease.’ As a result, current standard medical practices don’t target latent viruses.” (3) The study was published in the medical journal Pharmacology & Pharmacy in March 2014.

The Center for the Biology of Chronic Disease (CBCD) recommends that in light of the medical evidence, infected individuals take Gene-Eden-VIR or Novirin. The formula of these natural, antiviral supplements was designed to help the immune system target the latent EBV. Additionally, it was shown to reduce symptoms associated with EBV infection in two separate post-marketing clinical studies that followed FDA guidelines.

The formula of Gene-Eden-VIR and Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the formula of Gene-Eden-VIR and Novirin is effective against the herpes family of viruses. The Epstein Barr Virus (EBV) is a member of the herpes family. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with the EBV ... reported a safe decrease in their symptoms following treatment with (the formula of Novirin).” (4) The study authors also wrote that, “We observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (4)

Both products can be ordered through their websites here:

<http://www.gene-eden-vir.com>

and

<http://www.novirin.com>

Gene-Eden-VIR and Novirin are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses.

To date, Gene-Eden-VIR and Novirin are the only natural antiviral products on the market with published clinical studies that support their claims.

What treatments are available for EBV infections?

“A few antiviral drugs are available that were shown to inhibit EBV replication in cell culture. These

drugs include the acyclic nucleoside analogues aciclovir, ganciclovir, penciclovir, and their respective prodrugs valaciclovir, valganciclovir and famciclovir, the acyclic nucleotide analogues cidofovir and adefovir, and the pyrophosphate analogue foscarnet. However, clinical studies have shown that these drugs are mostly ineffective in humans.” (4) There are also natural antiviral products that studies show to be safe and effective in reducing EBV symptoms. Two of these products are Novirin and Gene-Eden-VIR.

Find us on Facebook here: <https://www.facebook.com/GeneEdenVIR>

Follow us on Twitter here: @HananPolansky

All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Deficient EBV-specific B- and T-cell response in patients with chronic fatigue syndrome. Published in January 2014.

<http://www.ncbi.nlm.nih.gov/pubmed/24454857>

(2) CDC - Chronic Fatigue Syndrome (CFS). Last updated on May 16, 2012.

<http://www.cdc.gov/cfs/>

(3) Gene-Eden-VIR Decreased Physical and Mental Fatigue in a Post Marketing Clinical Study That Followed FDA Guidelines; Results Support Microcompetition Theory. Published in March 2014.

<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=44234#.UzVBp6iSz90>

(4) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.

<http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101>

Greg Bennett
CBCD
585-250-9999
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.